Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Cubicin (daptomycin, legacy) by Year
Cubicin (daptomycin, legacy) — Worldwide reported growth YoY (%) (%)
Merck Cubicin (daptomycin, legacy): -41.0% in FY2020, down 11.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2020 figure comes from
“|| Cubicin | 46 | 32 | 39 | 36 | 152 | 88 | 67 | 52 | 50 | 257 | -27 | -28 | -41 | -40”
Source: Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cubicin (daptomycin, legacy) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Dec 31, 2020 | -41.0% | -11.0 pts | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2019 | Dec 31, 2019 | -30.0% | -26.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | -4.0% | +61.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | -65.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Cubicin (daptomycin, legacy) (%), annual FY2017–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-cubicin-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.